Community Bank & Trust Waco Texas lessened its holdings in shares of McKesson Co. (NYSE:MCK – Free Report) by 2.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,225 shares of the company’s stock after selling 25 shares during the period. Community Bank & Trust Waco Texas’ holdings in McKesson were worth $698,000 at the end of the most recent reporting period.
A number of other institutional investors have also modified their holdings of the business. Massachusetts Financial Services Co. MA grew its position in shares of McKesson by 2.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 4,943,520 shares of the company’s stock valued at $2,444,175,000 after buying an additional 138,685 shares during the last quarter. FMR LLC grew its position in McKesson by 17.3% in the 3rd quarter. FMR LLC now owns 2,968,239 shares of the company’s stock worth $1,467,557,000 after purchasing an additional 438,423 shares during the last quarter. Geode Capital Management LLC grew its position in McKesson by 1.0% in the 3rd quarter. Geode Capital Management LLC now owns 2,653,288 shares of the company’s stock worth $1,306,873,000 after purchasing an additional 26,299 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in McKesson by 55.8% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 1,189,377 shares of the company’s stock worth $588,048,000 after purchasing an additional 425,875 shares during the last quarter. Finally, Nordea Investment Management AB grew its position in McKesson by 20.0% in the 4th quarter. Nordea Investment Management AB now owns 975,935 shares of the company’s stock worth $558,606,000 after purchasing an additional 162,688 shares during the last quarter. Institutional investors own 85.07% of the company’s stock.
Insider Transactions at McKesson
In other news, EVP Leann B. Smith sold 579 shares of the stock in a transaction on Monday, December 9th. The shares were sold at an average price of $602.81, for a total transaction of $349,026.99. Following the transaction, the executive vice president now owns 1,443 shares in the company, valued at $869,854.83. This represents a 28.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.11% of the stock is currently owned by company insiders.
Analyst Upgrades and Downgrades
Get Our Latest Analysis on McKesson
McKesson Stock Performance
McKesson stock opened at $603.33 on Tuesday. The firm has a market cap of $76.59 billion, a PE ratio of 27.63, a P/E/G ratio of 1.30 and a beta of 0.52. The firm’s 50 day moving average price is $588.40 and its two-hundred day moving average price is $562.55. McKesson Co. has a twelve month low of $464.42 and a twelve month high of $637.51.
McKesson (NYSE:MCK – Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $8.03 earnings per share for the quarter, missing the consensus estimate of $8.60 by ($0.57). McKesson had a net margin of 0.82% and a negative return on equity of 181.26%. Equities analysts anticipate that McKesson Co. will post 32.69 EPS for the current fiscal year.
McKesson Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 1st. Stockholders of record on Monday, March 3rd will be paid a dividend of $0.71 per share. The ex-dividend date is Monday, March 3rd. This represents a $2.84 annualized dividend and a dividend yield of 0.47%. McKesson’s dividend payout ratio (DPR) is 13.00%.
McKesson Profile
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.
See Also
- Five stocks we like better than McKesson
- Overbought Stocks Explained: Should You Trade Them?
- Onsemi Stock: Signs Point to a Powerful Rebound
- Profitably Trade Stocks at 52-Week Highs
- Monday.com Stock Could Soar to New Highs—Here’s How
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Merck: 4 No-Brainer Reasons to Buy This Dip
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.